Hangzhou Jiuyuan Gene Engineering FY26 H1 net profit rises 1.2% to RMB 91.27 million; revenue falls 1.2% to RMB 630.95 million

• Hangzhou Jiuyuan Gene Engineering posted 1H 2026 profit of RMB 91.27 million, up 1.2%, as revenue slipped 1.2% to RMB 630.95 million.
• Gross margin narrowed 1.1 percentage points to 81.1%, as pharmaceutical services more than doubled to RMB 40.54 million on higher commissioned manufacturing.
• Revenue from sale of goods fell 5% to RMB 590.41 million, with management citing lower average selling prices for Guyoudao.
• R&D costs rose to RMB 69.3 million from RMB 49.63 million, reflecting higher investment as projects advanced.
• Completed renewals for centralized-procurement products Jiouting and Yinuojia; first Guyoudao export to Indonesia; no interim dividend declared.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12290774), on August 19, 2026, and is solely responsible for the information contained therein.